Top 10 Clinical Trends for March 2015

Ryan Syrek

Disclosures

March 20, 2015

#9 Clinical Trend: Candidiasis

A new drug is likely responsible for the increase in searches for this term. Viamet Pharmaceuticals announced that the drug VT-1161 has begun phase 2b clinical testing for treatment of recurrent vulvovaginal candidiasis. Having shown efficacy as an antifungal and a favorable safety profile, the drug may soon be available to treat the 5-8% of women in their child-bearing years who experience recurrent episodes of acute vulvovaginal candidiasis.

For more in-depth clinical information, see Candidiasis.

Comments

3090D553-9492-4563-8681-AD288FA52ACE
Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.
Post as:

processing....